Dainippon Sumitomo: Pipeline, Products, Performance, Potential

Table of Contents

Latest Results

EXECUTIVE SUMMARY

• Introduction
• Financial Performance 2005
  • Sales and Market Position
  • Income
    • Sales, Costs and Operating Income - Dainippon
  • Expenditure
    • Capital Expenditure
    • Capital Expenditure by Business Area - Dainippon
    • Capital Expenditure by Business Area - Dainippon
    • Capital Expenditure by Business Area - Sumitomo
    • Capital Expenditure by Business Area, 2005
    • R&d Expenditure
    • R&D Expenditure and Capital Expenditure - Dainippon
  • Divisional Performance
    • Sales by Business Area - Dainippon
    • Sales by Business Area - Dainippon
    • Operating Income by Business Area - Dainippon
    • Total Assets by Business Area - Dainippon
    • Total Assets by Business Area, 2005 - Dainippon
  • Geographic Performance
• Company strategy
• Product/R&D Overview
  • Key Products
    • Recent Product Launches
    • Recent Product Approvals
  • R&D Strategy
    • Key R&D Projects
  • R&D Pipeline Overview
  • Sales Forecast
    • Sales of Major Products
• Conclusions

PRODUCT PORTFOLIO/RESEARCH & DEVELOPMENT

• Major Products, Therapeutic Areas and Sales
• Sales of Major Products, 2005
• R&D Pipeline

• Cardiovascular and Respiratory System - Products
  • Major Launched Products
  • Amlodin
    • Sales
    • Key Markets/Indications/Formulations
    • Competitor Products
    • Lawsuits
    • Sales Forecasts
  • Amlodin Sales (2000A-2010E)
  • ProRenal
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Sales Forecasts
  • Prorenal Sales (2000A-2010E)
  • Synagis
    • Sales
    • Key Markets/Indications/Formulations
    • Safety Issues
    • Sales Forecast
  • Synagis Sales (2000A-2010E)
  • Other Cardiovascular Products
• Cardiovascular and Respiratory System - R&D
  • Ephedrine Nagai
  • Replagal
  • SMP-797
• Cardiovascular and Respiratory - Summary
  • Growth Factors
  • Limiting Factors
• Anti-infective - Products
  • Major Launched Products
  • Meropen/Merrem
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Competitor Products
    • Sales Forecasts
  • Meropen Sales (2000A-2010E)
  • Klaricid
    • Sales
    • Key Markets/Indication/Formulations
    • Competitor Products
    • Sales Forecast
  • Klaricid Sales (2000A-2010E)
• Anti-infective - R&D
  • AmBisome
• Anti-infective - Summary
  • Growth Potential
  • Limiting Factors
• Gastrointestinal - Products
  • Major Launched Products
  • Gasmotin
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Competitor Products
    • Sales forecast
  • Gasmotin Sales (2000A-2010E)
    • Clinical Trial Results
  • Other Products
• Gastrointestinal - R&D
• Gastrointestinal - Summary
  • Growth Potential
  • Limiting Factors
• Anti-allergenic - Products
  • Major Launched Products
  • Ebastel
    • Sales
    • Key Markets/Indications/Formulations
    • Competitor Products
    • Sales Forecast
  • Ebastel Sales (2000A-2010E)
  • Other Products
• Anti-allergenic - Summary
• Hormone/Biological - Products
  • Major Launched Products
  • Sumiferon
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Competitor Products
    • Sales Forecast
  • Sumiferon Sales (2000A-2010E)
• Hormones/Biological - Summary
• Central Nervous System - Products
  • Major Launched Products
  • Tremode/Excegran/Exogran/Zonegran
    • Sales
    • Key Markets/Indications/Formulations
    • Generic Competition
    • Further Development
    • Sales Forecast
  • Excegran Sales (2000A-2010E)
  • Other Products
• Central Nervous System - R&D
  • AC-3933
  • AC-5216
  • Lonasen
  • AS-3201
    • Clinical Trial Results
  • SM-13496
• Central Nervous System - Summary
  • Growth Potential
  • Limiting Factors
• Diabetes - Products
• Diabetes - R&D
  • Repaglinide
  • SMP-862
• Diabetes - Summary
  • Growth Potential
  • Limiting Factors
• Other - Products
  • Calsed
• Other - R&D
  • SM-11355
  • SMP-114
  • SMP-986

APPENDIX 1 - FINANCIAL PERFORMANCE

• Full Year Results 2005
  • Dainippon
  • Sales, Costs and Operating Income
  • Profitability and Research Ratios
  • R&D Expenditure and Capital Expenditure
  • Current Assets, Liabilities and Ratio
  • Assets, Cash and Liquidity
  • Employees and Productivity
  • Sumitomo Pharmaceuticals

APPENDIX 2 - KEY AGREEMENTS

• Almirall Prodesfarma SA
  • 15th May 2001
• Astellas Pharma
  • 26th September 2002
• AstraZeneca
  • 31st May 2000
  • 1st October 2000
  • 15th January 2004
• Conforma Therapeutics Corporation
  • 29th June 2005
• Eisai
  • 30th March 2004
  • 28th March 2005
• Gilead Sciences
  • 27th September 1996
• Idenix Pharmaceuticals Inc
  • 29th June 2001
  • 8th January 2003
• Kissei Pharmaceutical Co Ltd
  • 17th March 2005
• Kyorin Pharmaceutical Co Ltd
  • 16th March 2005
• Merck & Co
  • 5th July 2005
• Merck KGaA
  • 7th March 2003
• Merckle GmbH
  • 1st June 2004
• Mitsubishi Pharma Corporation
  • 28th December 2000
  • 25th March 2005
• Novartis
  • 12th February 2002
• Novo Nordisk
  • 17th September 2004
• Ono Pharmaceutical
  • 6th December 2005
• Protez Pharmaceuticals Inc
  • 17th May 2005
  • 24th August 2005
• Regeneron Pharmaceuticals Inc
  • 31st December 2001
• sanofi-aventis
  • 27th August 2003
• Schering-Plough
  • 12th September 2001
• Sunesis Pharmaceuticals Inc
  • 15th October 2003
• Taisho Pharmaceutical Co Ltd
  • 1st December 1999
• Licensing
• Co-Promotion/Co-Marketing

APPENDIX 3 - INFRASTRUCTURE

• Drug Research Division
• Drug Development Division
• Technology Research and Development Centre
• Research and Development Facilities
• Manufacturing Facilities

APPENDIX 4 - KEY PHARMACEUTICAL SUBSIDIARIES/JOINT VENTURES

• Subsidiaries
• Joint Ventures

APPENDIX 5 - PRODUCT INDEX